Pharmaceutical Contract Manufacturing Market (By Service: Pharmaceutical Manufacturing Services, Pharmaceutical API Manufacturing Services, Pharmaceutical FDF Manufacturing Services, Drug Development Services, Biologic Manufacturing Services, Biologic API Manufacturing Services, Biologic FDF Manufacturing Services; By End User: Big Pharmaceutical Companies, Small & Mid-Sized Pharmaceutical Companies, Other) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmaceutical Contract Manufacturing Market
5.1. COVID-19 Landscape: Pharmaceutical Contract Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmaceutical Contract Manufacturing Market, By Service
8.1. Pharmaceutical Contract Manufacturing Market, by Service, 2024-2033
8.1.1. Pharmaceutical Manufacturing Services
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Pharmaceutical API Manufacturing Services
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Pharmaceutical FDF Manufacturing Services
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Drug Development Services
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Biologic Manufacturing Services
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Biologic API Manufacturing Services
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Biologic FDF Manufacturing Services
8.1.7.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Pharmaceutical Contract Manufacturing Market, By End User
9.1. Pharmaceutical Contract Manufacturing Market, by End User, 2024-2033
9.1.1. Big Pharmaceutical Companies
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Small & Mid-Sized Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Generic Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Other End Users (Academic Institutes, Small CDMOs, and CROs)
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Pharmaceutical Contract Manufacturing Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.2. Market Revenue and Forecast, by End User (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End User (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.2. Market Revenue and Forecast, by End User (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End User (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End User (2021-2033)
Chapter 11. Company Profiles
11.1. Lonza Group
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Catalent, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Patheon (Now part of Thermo Fisher Scientific)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Recipharm AB
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Boehringer Ingelheim
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dr. Reddy's Laboratories
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Jubilant Life Sciences
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Fareva
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Vetter Pharma
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Evonik Industries
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample